Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 10 | 2015 | 140 | 2.320 |
Why?
|
| Cell Proliferation | 11 | 2021 | 1042 | 1.440 |
Why?
|
| Lectins | 5 | 2011 | 43 | 1.380 |
Why?
|
| Glioblastoma | 4 | 2015 | 161 | 1.350 |
Why?
|
| Glycoproteins | 4 | 2011 | 190 | 1.200 |
Why?
|
| Breast Neoplasms | 6 | 2021 | 1233 | 1.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 84 | 0.930 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2017 | 175 | 0.910 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2017 | 46 | 0.900 |
Why?
|
| Cell Line, Tumor | 15 | 2021 | 1573 | 0.900 |
Why?
|
| RNA Recognition Motif Proteins | 3 | 2021 | 5 | 0.880 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 3 | 2021 | 9 | 0.880 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 234 | 0.840 |
Why?
|
| Endothelial Cells | 5 | 2012 | 215 | 0.830 |
Why?
|
| RNA Helicases | 3 | 2021 | 99 | 0.830 |
Why?
|
| DNA Helicases | 3 | 2021 | 201 | 0.760 |
Why?
|
| Signal Transduction | 9 | 2020 | 3162 | 0.730 |
Why?
|
| Neoplasms | 5 | 2013 | 1376 | 0.670 |
Why?
|
| Adipokines | 5 | 2011 | 37 | 0.670 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2021 | 36 | 0.670 |
Why?
|
| Cadherins | 3 | 2017 | 90 | 0.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 588 | 0.660 |
Why?
|
| beta Catenin | 1 | 2021 | 100 | 0.650 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2021 | 203 | 0.620 |
Why?
|
| RNA, Small Interfering | 8 | 2020 | 986 | 0.610 |
Why?
|
| Cell Movement | 6 | 2020 | 482 | 0.610 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1389 | 0.610 |
Why?
|
| Carrier Proteins | 2 | 2015 | 718 | 0.590 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2015 | 15 | 0.530 |
Why?
|
| Mice, Inbred BALB C | 7 | 2021 | 869 | 0.520 |
Why?
|
| DNA Damage | 4 | 2018 | 298 | 0.520 |
Why?
|
| Proteoglycans | 3 | 2011 | 34 | 0.510 |
Why?
|
| Epithelial Cells | 2 | 2011 | 414 | 0.490 |
Why?
|
| Animals | 21 | 2021 | 21450 | 0.490 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 308 | 0.480 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 220 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 196 | 0.470 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.470 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2015 | 5 | 0.470 |
Why?
|
| Berberine | 1 | 2015 | 4 | 0.470 |
Why?
|
| Mice | 15 | 2021 | 11172 | 0.460 |
Why?
|
| Smad Proteins | 1 | 2015 | 23 | 0.450 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 77 | 0.440 |
Why?
|
| Autophagy | 1 | 2017 | 239 | 0.430 |
Why?
|
| Laminin | 2 | 2011 | 81 | 0.430 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 22 | 0.420 |
Why?
|
| Chitinase-3-Like Protein 1 | 5 | 2011 | 14 | 0.420 |
Why?
|
| Mice, SCID | 6 | 2011 | 518 | 0.410 |
Why?
|
| Cisplatin | 2 | 2012 | 145 | 0.410 |
Why?
|
| Collagen | 2 | 2011 | 135 | 0.410 |
Why?
|
| Mice, Nude | 5 | 2021 | 287 | 0.400 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 319 | 0.370 |
Why?
|
| Hormones | 1 | 2011 | 62 | 0.340 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 29 | 0.340 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 369 | 0.340 |
Why?
|
| Cell Polarity | 1 | 2011 | 110 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 216 | 0.340 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 76 | 0.330 |
Why?
|
| Humans | 27 | 2021 | 65632 | 0.330 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 644 | 0.330 |
Why?
|
| GTPase-Activating Proteins | 1 | 2011 | 69 | 0.330 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 1226 | 0.330 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 83 | 0.320 |
Why?
|
| Autoantigens | 1 | 2011 | 140 | 0.310 |
Why?
|
| Ribonucleoproteins | 1 | 2011 | 116 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 289 | 0.310 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 16 | 0.310 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 233 | 0.310 |
Why?
|
| Apoptosis | 5 | 2018 | 1100 | 0.300 |
Why?
|
| HCT116 Cells | 4 | 2016 | 50 | 0.290 |
Why?
|
| Peptide Fragments | 1 | 2011 | 418 | 0.290 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 218 | 0.290 |
Why?
|
| Myosin Light Chains | 1 | 2008 | 9 | 0.290 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 14 | 0.290 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 25 | 0.280 |
Why?
|
| Paclitaxel | 1 | 2009 | 102 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2008 | 6 | 0.280 |
Why?
|
| Peptides | 1 | 2012 | 593 | 0.270 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 20 | 0.270 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 285 | 0.270 |
Why?
|
| Muscle Proteins | 1 | 2008 | 117 | 0.270 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 526 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 466 | 0.260 |
Why?
|
| Cytoplasm | 1 | 2008 | 283 | 0.250 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 241 | 0.240 |
Why?
|
| Transfection | 3 | 2015 | 700 | 0.240 |
Why?
|
| Mesoderm | 1 | 2006 | 89 | 0.230 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 223 | 0.230 |
Why?
|
| Enediynes | 2 | 2016 | 3 | 0.230 |
Why?
|
| Aminoglycosides | 2 | 2016 | 11 | 0.230 |
Why?
|
| Down-Regulation | 3 | 2012 | 324 | 0.230 |
Why?
|
| Telomerase | 1 | 2004 | 30 | 0.210 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 501 | 0.210 |
Why?
|
| Neovascularization, Physiologic | 1 | 2004 | 113 | 0.200 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 128 | 0.200 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 83 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 426 | 0.200 |
Why?
|
| Cell Line | 4 | 2011 | 2029 | 0.200 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 178 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2017 | 344 | 0.190 |
Why?
|
| Blotting, Western | 2 | 2015 | 611 | 0.190 |
Why?
|
| Female | 9 | 2021 | 34294 | 0.180 |
Why?
|
| Neoplasm Transplantation | 3 | 2014 | 167 | 0.170 |
Why?
|
| Drug Combinations | 2 | 2011 | 167 | 0.170 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 65 | 0.170 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2020 | 31 | 0.160 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.160 |
Why?
|
| Enzyme Activation | 2 | 2013 | 391 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 80 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 81 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 897 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2013 | 963 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 28 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 43 | 0.140 |
Why?
|
| Pyridazines | 1 | 2018 | 10 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2010 | 65 | 0.130 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 58 | 0.120 |
Why?
|
| Disease Progression | 2 | 2011 | 1225 | 0.120 |
Why?
|
| RNA Interference | 2 | 2011 | 647 | 0.120 |
Why?
|
| Comet Assay | 1 | 2015 | 11 | 0.120 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2015 | 8 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 31 | 0.120 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 61 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2016 | 121 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 135 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2014 | 142 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 205 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2020 | 551 | 0.100 |
Why?
|
| Amino Alcohols | 1 | 2013 | 1 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 63 | 0.100 |
Why?
|
| Rituximab | 1 | 2014 | 89 | 0.100 |
Why?
|
| Sphingosine | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2013 | 26 | 0.100 |
Why?
|
| Ceramides | 1 | 2013 | 25 | 0.100 |
Why?
|
| Thiazoles | 1 | 2013 | 45 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 47 | 0.090 |
Why?
|
| Cinnamates | 1 | 2012 | 9 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 797 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2012 | 202 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 18 | 0.090 |
Why?
|
| Prolactin | 1 | 2011 | 40 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 240 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2011 | 102 | 0.090 |
Why?
|
| Caseins | 1 | 2011 | 42 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 43 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 35 | 0.090 |
Why?
|
| Milk | 1 | 2011 | 47 | 0.080 |
Why?
|
| Gamma Rays | 1 | 2011 | 32 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 97 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2011 | 33 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 542 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 37 | 0.080 |
Why?
|
| Lactation | 1 | 2011 | 77 | 0.080 |
Why?
|
| Vimentin | 1 | 2010 | 19 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2011 | 192 | 0.080 |
Why?
|
| Biglycan | 1 | 2009 | 1 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 17 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 16 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 289 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 38 | 0.070 |
Why?
|
| Vincristine | 1 | 2009 | 26 | 0.070 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 6 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 435 | 0.070 |
Why?
|
| Stress Fibers | 1 | 2008 | 2 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2011 | 617 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2009 | 77 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 44 | 0.070 |
Why?
|
| Survival Rate | 1 | 2011 | 847 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 34 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 218 | 0.070 |
Why?
|
| Plasmids | 1 | 2009 | 294 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1588 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 854 | 0.070 |
Why?
|
| Benzamides | 1 | 2008 | 69 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1979 | 0.070 |
Why?
|
| Insulin | 1 | 2011 | 696 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 105 | 0.070 |
Why?
|
| Piperazines | 1 | 2008 | 86 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2008 | 141 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 446 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2008 | 144 | 0.060 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2018 | 47 | 0.060 |
Why?
|
| Receptors, Vitronectin | 1 | 2006 | 4 | 0.060 |
Why?
|
| Integrins | 1 | 2006 | 109 | 0.060 |
Why?
|
| Biomarkers | 1 | 2011 | 1487 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 95 | 0.060 |
Why?
|
| Receptor, TIE-1 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2004 | 7 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2004 | 31 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2004 | 114 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1193 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 929 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 709 | 0.050 |
Why?
|
| Male | 3 | 2020 | 31281 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nanoconjugates | 1 | 2020 | 5 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 129 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2020 | 70 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 116 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6946 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2016 | 28 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 101 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 858 | 0.030 |
Why?
|
| Adult | 1 | 2011 | 17507 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 31 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 40 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Middle Aged | 1 | 2011 | 18431 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2014 | 21 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 38 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 689 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 104 | 0.020 |
Why?
|
| Random Allocation | 1 | 2014 | 200 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2014 | 108 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2020 | 852 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1580 | 0.020 |
Why?
|